{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:41:46Z","timestamp":1793018506905,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005821","name":"DHHS Office of the Secretary","doi-asserted-by":"publisher","award":["3OT2OD032581-01S1"],"award-info":[{"award-number":["3OT2OD032581-01S1"]}],"id":[{"id":"10.13039\/100005821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is wide variation in opioid prescribing practices, including opioid quantity and risk mitigation strategies (RMS). Urine drug tests (UDT) are often used as a RMS for patients prescribed opioids. There is a lack of standardized recommendations for these tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aim to evaluate differences in prescribing practices, including opioid prescriptions and UDT as an RMS, among patients with multiple opioid prescriptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective analysis of a national outpatient database of long-term adult opioid prescriptions (\u2265\u20093 prescriptions over a period of at least 120-days) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Demographics, abuse history, morphine milligram equivalents (MME), UDT, and frequency were variables of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      96,994 met the inclusion criteria. Hispanic patients were prescribed less MME\/day than non-Hispanics. Examining patients prescribed\u2009\u2265\u200950 MME\/day, the highest rates were in American Indian\/Alaskan native (8.4%) and White patients (7.5%). At least one UDT was performed in 18,203 (18.8%) patients. When categorized by race, UDTs showed that 25.8% of American Indian\/Alaska native, 22.7% of Black patients, 19.2% of multiple races, 18.0% of White patients, 13.5% of Hawaiian\/Pacific Islanders, and 12.7% of Asian patients underwent UDTs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among the category of\u2009\u2265\u20097 UDTs, Black patients (1.3%) received the most. Upon regression modeling, females (OR 0.94) and uninsured patients (OR 0.66) were less likely to undergo UDT. Among MME categories, patients prescribed 75\u201399 MME\/day had the highest likelihood of UDT (OR 2.4). Those with opioid use disorder (OR 2.64) and tobacco use (OR 1.083) were tested more frequently. When examining race, American Indian\/Alaskan natives (OR 1.36), Black patients (OR 1.36), and multiple races (OR 1.245) were more likely to undergo UDT than White patients (reference).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is variation in opioid prescribing practices, including opioid quantity and UDT. White patients receive more opioids but less UDT than other populations. Improvements are needed to ensure universal opioid prescribing practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40615-025-02474-x","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:22:43Z","timestamp":1747995763000},"page":"3006-3016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urine Drug Testing Among Long-term Opioid Prescribed Patients: Disparities and Opportunities"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8947-3370","authenticated-orcid":false,"given":"Brian K.","family":"Yorkgitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fern","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Brat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2474_CR1","unstructured":"Center for Disease Control and Prevention. About opioid prescriptions. Available at: https:\/\/www.cdc.gov\/overdose-prevention\/about\/prescription-opioids.html#:~:text=More%20than%20130%20million%20opioid,for%20as%20long%20as%20necessary. Accessed 30 Aug 2024."},{"issue":"2","key":"2474_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1526-4637.2005.05031.x","volume":"6","author":"DL Gourlay","year":"2005","unstructured":"Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107\u201312.","journal-title":"Pain Med"},{"issue":"3","key":"2474_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guidelines for prescribing opioid for pain- United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395.","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"2474_CR4","first-page":"58","volume":"16","author":"A Rambachan","year":"2021","unstructured":"Rambachan A, Fang MC, Prasad P, Iverson N. Racial and ethnic disparities in discharge opioid prescribing from a hospital medicine service. Soc Hosp Med. 2021;16(10):58\u2013595.","journal-title":"Soc Hosp Med."},{"issue":"9","key":"2474_CR5","doi-asserted-by":"publisher","first-page":"e2123333","DOI":"10.1001\/jamahealthforum.2021.2333","volume":"2","author":"DP Ly","year":"2021","unstructured":"Ly DP. Association of patient race and ethnicity with differences in opioid prescribing by primary care physicians for older adults with new low back Pain. JAMA Health Forum. 2021;2(9):e2123333.","journal-title":"JAMA Health Forum"},{"issue":"14","key":"2474_CR6","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.22.01413","volume":"41","author":"AC Enzinger","year":"2023","unstructured":"Enzinger AC, Ghosh K, Keating NL, Culter DM, Clark CR, Florez N, Landrum MB, Wright AA. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol. 2023;41(14):2511\u201322.","journal-title":"J Clin Oncol"},{"key":"2474_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3122\/jabfm.2022.220360R1","volume":"36","author":"AL Agnoli","year":"2023","unstructured":"Agnoli AL, Howe R, Magnan E, Jerant A, Colby D, Franks P. Urine drug testing among patients prescribed long-term opioid therapy: patient and clinician factors. J Am Board Fam Med. 2023;36:537\u201341.","journal-title":"J Am Board Fam Med"},{"key":"2474_CR8","doi-asserted-by":"publisher","first-page":"209243","DOI":"10.1016\/j.josat.2023.209243","volume":"159","author":"RE Barenie","year":"2024","unstructured":"Barenie RE, Bateman BT, Connery HS, Tscogiania T, Kesselheim AS. Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015\u20132019. J Subst Use Addict Treat. 2024;159:209243.","journal-title":"J Subst Use Addict Treat"},{"key":"2474_CR9","unstructured":"Kale N. Urine drug tests: ordering and interpretation. Am Fam Physician. 2019; 99(1):33\u201339. https:\/\/www.aafp.org\/pubs\/afp\/issues\/2019\/0101\/p33.html"},{"issue":"12","key":"2474_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jpain.2019.05.006","volume":"20","author":"M Mayhew","year":"2019","unstructured":"Mayhew M, DeBar L, Deyo RA, Kerns RD, Goulet JL, Brandt CA, Von Korff M. Development and assessment of a crosswalk between ICD-9 and ICD-10 to identify patients with common pain conditions. J Pain. 2019;20(12):1429\u201345.","journal-title":"J Pain"},{"key":"2474_CR11","unstructured":"AIM-AHEAD. OCHIN and OCHIN data. Available at: https:\/\/www.aim-ahead.net\/data-and-research-core\/about-ochin-ochin-data\/. Accessed 28 Aug 2024."},{"key":"2474_CR12","unstructured":"National Library of Medicine. RxNorm Files. Available at: https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm\/docs\/rxnormfiles.html. Accessed 1 Aug 2023."},{"key":"2474_CR13","unstructured":"New York State Department of Health. New York State (NYS) - issued formulation morphine milligram equivalent (MME) conversion table guidance. Available at: https:\/\/apps.health.ny.gov\/pub\/ctrldocs\/bne\/nyosammeformulation.pdf. Accessed 20 Aug 2024."},{"issue":"1","key":"2474_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/pm\/pnx285","volume":"19","author":"CE Argoff","year":"2017","unstructured":"Argoff CE, Alford DP, Fudin J, Adler JA, Bair MJ, Dart RC, Gandolfi R, McCarberg BH, Gudin JA, Polomano RC, Wester LR. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med. 2017;19(1):97\u2013117.","journal-title":"Pain Med"},{"issue":"4","key":"2474_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.amepre.2020.10.011","volume":"60","author":"SA Taha","year":"2021","unstructured":"Taha SA, Westra J, Raji MA, Kuo YF. Trends in urine drug testing among long-term opioid users, 2012\u20132018. Am J Prev Med. 2021;60(4):546\u201351.","journal-title":"Am J Prev Med."},{"key":"2474_CR16","unstructured":"Schulte F, Lucus E. Liquid gold: pain doctors soak up profits by screening urine for drugs. KFF, 2017. Available at: https:\/\/kffhealthnews.org\/news\/liquid-gold-pain-doctors-soak-up-profits-by-screening-urine-for-drugs\/. Accessed 8 Jul 2024."},{"key":"2474_CR17","unstructured":"Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Accessed 8 Jul 2024."},{"key":"2474_CR18","doi-asserted-by":"publisher","unstructured":"Coffin PO, Rowe C, Oman N, Sincheck K, Santos GM, Faul M, Bagnulo R, Mohamed D, Vittinghoff E. Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PLoS One. Available at: https:\/\/doi.org\/10.1371\/journal.pone.0232538. Accessed 8 Jul 2024","DOI":"10.1371\/journal.pone.0232538"},{"issue":"12","key":"2474_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/pm\/pnad103","volume":"24","author":"B Andraka-Christou","year":"2023","unstructured":"Andraka-Christou B, McAvoy E, Gordon AJ, Ohama M, Brach M, Taylor EA, Vaiana M, Saloner B, Stein BD. Urine drug testing in the context of opioid analgesic prescribing for chronic pain: a content analysis of U.S. state laws in 2022. Pain Med. 2023;24(12):1306\u201317.","journal-title":"Pain Med."},{"issue":"4","key":"2474_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/amiajnl-2014-002744","volume":"21","author":"JE DeVoe","year":"2014","unstructured":"DeVoe JE, Gold R, Conttreel E, Bauer V, Brickman A, Puro J, Nelson C, Mayer KH, Sears A, Burdick T, Merrell J, Matthews P, Fields S. The ADVANCE network: accelerating data values across a national community health center network. J Am Med Inform Assoc. 2014;21(4):591\u20135.","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"2474_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1370\/afm.1279","volume":"9","author":"JE DeVoe","year":"2011","unstructured":"DeVoe JE, Gold R, McIntire P, Puro J, Chavie S, Gallia CA. Electronic heath records vs medicaid claims: completeness of diabetes preventative care data in community health centers. Ann Fam Med. 2011;9(4):351\u20138.","journal-title":"Ann Fam Med"},{"issue":"6","key":"2474_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/bja\/aex316","volume":"119","author":"R Lawrence","year":"2017","unstructured":"Lawrence R, Mogford D, Calvin L. Systematic review to determine which validated measurement tools can be used to assess risk of problematic analgesic use in patients with chronic pain. Br J Anesth. 2017;119(6):1092\u2013109.","journal-title":"Br J Anesth"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-025-02474-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:20:11Z","timestamp":1783524011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-025-02474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2474"],"URL":"https:\/\/doi.org\/10.1007\/s40615-025-02474-x","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was deemed exempt by the University of Florida and Harvard University IRBs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Waived due to deidentified administrative database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}